Optymum SS UK Ltd

11/05/2026

We are pleased to share that our Founder, Dr Daniel A Mamphey, has been published in The Biomedical Scientist.

The Biomedical Scientist is the official publication platform of the Institute of Biomedical Science, the UK’s leading professional body for biomedical scientists and laboratory professionals.

His article, “Leadership Beyond the Bench,” argues that Biomedical Scientists should also be Builders and explores why Biomedical Scientists should not only be trained to work within laboratory systems but also encouraged to improve, redesign, and build beyond them.

At Optymum SS (UK) Ltd, this message reflects a key part of our mission.

Biomedical Scientists are not just technical professionals. They are problem-solvers, system-thinkers, innovators, educators, and leaders in laboratory medicine.

As diagnostic services face workforce pressures, digital transformation, AI adoption, and increasing demand, the profession needs people who can do more than perform tasks well. It needs professionals who can see problems clearly and help build better solutions.

Read the full article here:

Biomedical Scientists should not only be trained to work well within laboratory systems, but also encouraged to improve, redesign and build beyond, argues biomedical scientist Dr Daniel A Mamphey.

19/01/2026

In today’s AI-driven world, we’re not short of analysis.

We’re short of citable, defensible, decision-grade narratives.

We often see researchers, founders, and healthcare-adjacent innovators who say the same thing:

“We know this is a big problem. We just can’t point to a single, credible document that we can cite as a reference, which frames and quantifies it properly.”

That gap quietly kills:

• Research
• Grant applications
• Adoption conversations
• Investor confidence
• Strategic momentum

At Optymum SS, we’ve formalised a service to solve exactly this problem.

We produce Insight Briefs, Position Papers, and System & Market Landscape Reports that turn under-defined, under-quantified problems into named, attributable, citable documents that can safely be used.

If this resonates you can comment or DM to receive a short overview PDF, with prices and use cases, for anyone who keeps hitting this invisible wall.

25/09/2025

Most delays aren’t about the science—they’re about basics that weren’t tidied early.

1. Docs not truly “submission-ready.” Stability notes, assay/method write-ups, specs in different formats.
Fix: one pass to align terms, tabulate specs/stability, and map each claim to its source.

2. Reviewer pack hard to follow. Great data still stalls if people can’t find it fast.
Fix: cover note stating the decision, a simple contents map, and short summaries before the appendices.

3. Study plan doesn’t match manufacturing docs (CMC = how it’s made/tested).
Fix: quick cross-walk to reconcile names, dates, and versions.

Want our 1-page pre-submission checklist? Comment CHECKLIST or DM CHECKLIST and we’ll send it. Share your target date and we’ll mark your top 3 risks in 15 minutes.

Optymum SS — Chartered Scientists. Practical help, small sprints, fast wins.

21/07/2025

🚨 We're Hiring Scientific Partners (Chartered or Equivalent) 🚨

Are you a Chartered Scientist or experienced professional in life sciences, diagnostics, or digital health looking for meaningful work outside the traditional job structure?

At Optymum SS (UK) Ltd, we're expanding, with a growing pipeline and a steady stream of qualified client leads, and building a network of scientific partners to collaborate on exciting consultancy and innovation projects. This is a freelance partnership opportunity with profit-share earnings, not a salaried role. It’s ideal for independent thinkers who want flexibility, impact, and a seat at the table.

✔ Flexible working
✔ Project-by-project involvement
✔ 49% revenue share per project
✔ Remote or hybrid
✔ Contractual partnership structure
✔No marketing required

🔗 Apply now via Indeed: https://uk.indeed.com/job/scientific-partner-e9815947451a9844

Optymum SS (UK) Ltd

09/01/2025

We are excited to announce the remarkable attainment, that HemoVisionAI our pioneering R&D project, poised to launch as a new business line, has already made a significant impact. Within hours of its initial introduction on F6S, one of the world’s largest deal marketplaces, it has been ranked among the top 5 telemedicine companies and startups in the United Kingdom for January 2025. This early recognition, despite the company not yet being formally incorporated, underscores the immense potential and groundbreaking nature of this innovative venture.“

Be among the first to experience HemoVisionAI. Sign up here --> https://www.optymumss.com/hemovisionai/ and gain early access to our revolutionary AI-powered platform when it launches.

in Healthcare

19/11/2022

Read the full article here 👉 https://www.sciencenews.org/article/tiger-sharks-discover-worlds-largest-seagrass-prairie

18/11/2022

For more information, visit our website!
https://www.optymumss.com

17/11/2022

Read the full article here 👉 https://www.sciencenews.org/article/world-population-8-billion-humans-earth

14/11/2022

Read the full article here 👉https://www.sciencenews.org/article/embryos-biological-clock-development